| Phosphate binder product use, by DOPPS country and cross-section |
| Ca-based only | Sevelamer only | Ca + sev. only | Other | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N Ptnts | Wgtd % | N Ptnts | Wgtd % | N Ptnts | Wgtd % | N Ptnts | Wgtd % | ||
| DOPPS Country | DOPPS Cross-section | 119 | 56.3% | 37 | 18.1% | 20 | 10.5% | 33 | 15.1% |
| AusNZ | D4(2010) | ||||||||
| Belgium | D4(2010) | 157 | 54.4% | 43 | 13.0% | 84 | 27.8% | 17 | 4.8% |
| Canada | D4(2010) | 169 | 73.1% | 31 | 9.6% | 30 | 9.6% | 18 | 7.7% |
| France | D4(2010) | 75 | 31.2% | 73 | 30.2% | 58 | 27.2% | 30 | 11.3% |
| Germany | D4(2010) | 196 | 54.6% | 63 | 15.7% | 53 | 15.8% | 60 | 13.8% |
| Italy | D4(2010) | 70 | 22.6% | 149 | 42.8% | 59 | 18.7% | 50 | 15.8% |
| Japan | D4(2010) | 678 | 58.5% | 160 | 13.2% | 257 | 19.9% | 98 | 8.3% |
| Spain | D4(2010) | 97 | 30.7% | 92 | 32.4% | 58 | 18.2% | 60 | 18.8% |
| Sweden | D4(2010) | 91 | 26.3% | 101 | 31.7% | 69 | 20.8% | 68 | 21.2% |
| UK | D4(2010) | 146 | 59.2% | 66 | 22.7% | 10 | 2.9% | 40 | 15.2% |
| US | D4(2010) | 990 | 37.3% | 1,045 | 43.6% | 340 | 12.7% | 140 | 6.4% |
| Medications reported as prescribed (not necessarily taken) in previous week, among treated patients |
Please see additional methodological information in the Data Sources and Methods section.